British Journal of Psychiatry 1988-09-01

Criteria for evaluating improvement in schizophrenia in psychopharmacological research (with special reference to gamma endorphin fragments).

R Manchanda, S R Hirsch, T R Barnes

Index: Br. J. Psychiatry 153 , 354-8, (1988)

Full Text: HTML

Abstract

A review of treatment trials with DT gamma E revealed widely discrepant results. Relevant variables were the variety of measures employed for monitoring psychotic symptoms, and the different criteria used to judge the degree of improvement. The authors suggest a uniform outcome criterion for early trials of new treatments, which would generate more consistent and comparable results between studies, and give a stronger indication of the value of the treatment under test. When the data from the various treatment trials of DT gamma E were reanalysed, applying a uniform outcome criterion of improvement of a change of 80% or more on rating-scale score, the results were more consistent than would have been suspected from the original reports.


Related Compounds

Related Articles:

Interaction between des-Tyr1-gamma-endorphin and HLA class I molecules: serological detection of an HLA-A2 subtype.

1985-01-01

[Immunogenetics 22(4) , 309-14, (1985)]

Des-tyrosine-gamma-endorphin effects on morphine analgesia in mice.

1993-01-01

[Gen. Pharmacol. 24(1) , 83-8, (1993)]

Short-lived effect of (Des-Tyr)-gamma-endorphin in schizophrenia.

1983-12-01

[Psychiatry Res. 10(4) , 243-52, (1983)]

Subchronic treatment with fragments of beta-endorphin prevents electroencephalographic seizures and behavioral alterations induced by centrally administered beta-endorphin in the rabbit.

1994-02-01

[J. Pharmacol. Exp. Ther. 268(2) , 1040-50, (1994)]

A treatment trial with an analog of thyrotropin-releasing hormone (DN-1417) and des-tyrosine-gamma-endorphin in schizophrenia.

1986-10-01

[Int. Clin. Psychopharmacol. 1(4) , 303-13, (1986)]

More Articles...